$1.1B Rosenwald Private Wealth Joins Indivisible Partners

Baltimore-based firm joins wave of teams choosing ownership-focused model

CLEARWATER, Fla., Oct. 13, 2026 — Indivisible Partners (“Indivisible”), an advisor-owned growth partnership, announced last week that Rosenwald Private Wealth, a $1.1 billion advisory team serving high-net-worth and ultra-high-net-worth clients, has joined the firm from RBC Wealth Management.

Rosenwald’s move comes amid a period of significant growth for Indivisible. Six advisory teams representing over $3 billion in assets have affiliated with the platform in recent months, reflecting growing interest among established wealth management practices in a model that combines independence, ownership, and enterprise-level support.

Rosenwald Private Wealth’s transition also underscores a broader shift among advisors serving affluent clients who are seeking full control over their future while maintaining the capabilities required to serve complex client needs.

“What’s notable isn’t simply the number of firms that have chosen our platform,” said John Thiel, Executive Chairman and founder of Indivisible Partners. “It’s the caliber and scale of the practices making that decision. Rosenwald Private Wealth is another indication that our version of independence has become the preferred option for established advisory teams serving sophisticated clients.”

Unlike traditional models, Indivisible Partners enables advisors to retain full ownership of their business while participating in the growth and equity of the broader organization. The platform provides access to family office services, as well as business development support, marketing consulting, growth coaching, and succession-planning resources.

“As we evaluated the future of our business, we wanted a model that allowed us to own what we’ve built while expanding what would be possible for our clients,” said Beth Rosenwald, the firm’s founder. “Indivisible offered the combination of independence, flexibility, and active support that was the best fit for how we want to continue to serve our clients and grow the business in the years ahead.”

Rosenwald Private Wealth has been serving the ultra-high-net-worth segment for nearly three decades. Their shift follows an increasing trend of $1 billion+ firms moving into the independent space.

“Exceptional advisory practices want the freedom to shape their futures without compromise,” Thiel added. “We believe that trend will continue as more advisors evaluate what ownership means for their firms. With us, they can find the deep and wide set of innovative solutions that they’ve never been able to offer. From new thinking on tax alpha to untapped wealth planning approaches to radically new user-friendly technology, we’ve created the firm advisors have been asking for.”

About Indivisible Partners 

Indivisible Partners is a privately held, independent advisory firm founded by experienced industry leaders and former advisors to redefine what independence can mean for elite advisory teams. The firm combines an innovative, integrated platform with true ownership, high-touch support, and a collaborative culture—empowering advisors to deliver better outcomes for their clients and build lasting enterprise value on their own terms. Indivisible Partners is headquartered in Clearwater, FL, and operates as a federally registered investment advisor. For more information, please visit:  www.indivisible.com. 

About Rosenwald Private Wealth 

Rosenwald Private Wealth is an independent wealth management firm based in Baltimore, Maryland, with investment advisory services offered through Indivisible Partners, LLC. The firm provides comprehensive wealth planning, investment management, retirement planning, estate and legacy planning strategies, and family-focused financial guidance for individuals and multigenerational families. Led by Beth Rosenwald, Matthew Kunkel, and Leksi Kovalerchik, the team is dedicated to helping clients navigate complex financial decisions through long-term relationships, personalized advice, and thoughtful stewardship.

SOURCE Indivisible Partners

Fesarius Therapeutics to Showcase DermiSphere™ hDRT at Plastic Surgery The Meeting 2026

Company to host scientific symposium featuring leading surgeons and participate in ASPS Ventures roundtable as the fund’s inaugural investment

NEW YORK, Oct. 13, 2026 — FesariusTherapeutics, a commercial-stage medical technology company reimagining dermal repair, today announced its participation in Plastic Surgery The Meeting (“PSTM”) 2026, taking place October 15–18 at the George R. Brown Convention Center in Houston, Texas.

Fesarius will showcase DermiSphere™ hDRT, the first and only dual-density collagen hydrogel dermal regeneration template that creates a dual-density scaffold designed to support tissue integration, rapid vascularization and new tissue formation. Attendees can learn more by visiting the Fesarius team at booth #1920 and by attending the following events:

Scientific Symposium: From Benchtop to Bedside – Advancing Dermal Regeneration with Hydrogel Technology

Saturday, October 17, 2026 | 3:30–4:30 p.m. CDT
Where: CC, Innovation Theater B, Exhibit Hall DE

A scientific symposium examining the foundational science and clinical application of DermiSphere™ hDRT. The program will explore the technology’s dual-density microarchitecture, designed to support tissue integration, rapid vascularization, and new tissue formation, alongside recently published clinical data and emerging surgeon experience across complex wound and reconstructive applications.

Featuring:

  • Jason Spector, MD, — Speaker and Moderator: Founder and Chief Medical Officer of Fesarius Therapeutics and Chief, Division of Plastic & Reconstructive Surgery at Weill Cornell Medicine.
  • Brendan MacKay, MD, —Speaker: Associate Professor of Orthopedic Surgery and UMC Director of Hand and Microvascular Surgery at Texas Tech University Health Sciences Center.

ASPS Ventures Expert Panel & Happy Hour: Connecting Plastic Surgery, Innovation and Investment

Saturday, October 17, 2026 | 6:30–8:00 p.m. CDT
WHERE: Hilton Hotel, Houston | Ballroom of Americas C

An Expert Panel & Happy Hour featuring Fesarius President and Chief Executive Officer Tom Roueche and hosted by ASPS Ventures, a medtech venture fund bringing together plastic surgeons, innovation and investment to advance technologies addressing unmet clinical needs.

Meet Fesarius at Booth #1920

For more information, visit www.fesariustherapeutics.com.

About Fesarius Therapeutics

Fesarius Therapeutics is a commercial-stage medical technology company reimagining dermal repair through innovations in biomaterials. Its flagship product, DermiSphere™ hDRT, is the first and only dual-density collagen hydrogel dermal regeneration template, designed to support the body’s natural healing process. Developed from technology discovered by plastic surgeon Jason Spector, MD at Weill Cornell Medicine, DermiSphere™ hDRT combines a collagen hydrogel with denser collagen microspheres to support dermal tissue regeneration.

For more information, visit www.fesariustherapeutics.com.

Media Contact
Jennifer Hanley
347-819-0402

DermiSphere Sales Contact
Tim O’Brien
630-253-5056

SOURCE FesariusTherapeutics, Inc

HealthpointCapital Makes Significant Investment in Ospitek, a Leading Provider of Surgical Operations and Patient Flow Intelligence Software

SAN DIEGO, Oct. 13, 2026 — HealthpointCapital, the leading private equity firm focused exclusively on musculoskeletal healthcare, today announced a significant investment in Ospitek, Inc. (“Ospitek” or the “Company”). Founded to address operational inefficiencies across surgical settings, Ospitek’s platform delivers real-time visibility across the surgical episode of care, enabling healthcare facilities to optimize operations, enhance communication, and improve patient experiences.

Ospitek’s technology leverages a combination of artificial intelligence, digital infrastructure, automation, and analytics to synchronize teams, automate communication, and generate real-time operational intelligence. The platform helps healthcare organizations identify inefficiencies, benchmark performance, and make data-driven decisions that improve patient throughput and operating room performance.

“Hospitals and surgery centers are laser-focused on driving efficiency while improving patient, surgeon and staff satisfaction”, said Mike Mogul, Managing Partner of HealthpointCapital, “Ospitek gives all of those stakeholders a transparent and informative view of the surgical journey while enabling significant improvements in care delivery capacity for the facility.”

Dr. Slim Souissi, Ph.D., Chief Executive Officer of Ospitek, added: ” Ospitek’s partnership with HealthpointCapital will allow us to accelerate innovation, expand our capabilities, and bring our technology to more surgical facilities across the country. The future of surgery is connected, intelligent, predictive, and patient-centered. And we are excited to help build it.”

HealthpointCapital will support continued investment in Ospitek’s technology platform, commercial organization, customer success capabilities, and product innovation. The Company is well-positioned to capitalize on the growing demand for workflow automation and operational intelligence solutions across ambulatory surgery centers, specialty hospitals, and broader healthcare settings.

Along with HealthpointCapital’s investment in SteriCUBE®, a leading system for surgical equipment flow, Ospitek continues the focus of developing platforms that will enable healthcare facilities, especially ambulatory surgical centers, to scale effectively and efficiently.

Transaction details were not disclosed. McDermott Will & Schulte LLP provided legal counsel to HealthpointCapital.

About HealthpointCapital
HealthpointCapital is the leading private equity firm focused exclusively on the musculoskeletal sector. Led by Managing Partner Mike Mogul together with Matt Link, Milen Todorov, Gary Stevenson, Lisa Holt and Bill Johnson, HealthpointCapital brings together extensive medical device operating experience, a strong private equity track record, and an extensive network of clinical, commercial and strategic company relationships to help portfolio companies accelerate growth. Notable exits for HealthpointCapital include CrossRoads Extremity Systems (acquired by Johnson & Johnson DepuySynthes), OrthoSpace (acquired by Stryker), Blue Belt Technologies (acquired by Smith+Nephew) and BioHorizons (acquired by Henry Schein).

For additional information, visit www.healthpointcapital.com.

About Ospitek, Inc.
Ospitek provides AI- and IoT-powered surgical operations software that delivers real-time visibility across the entire patient journey and helps healthcare providers improve throughput, operating room utilization and patient experience.

For additional information, visit www.ospitek.net.

For investor or media inquiries, please contact: Tessa Cicitta, HealthpointCapital, 212-935-7780 or [email protected].

SOURCE HealthpointCapital

Helium Ventures Announces Jitsu Acquisition and Product Expansion

Founded in 2020, Jitsu participated in Y Combinator’s Summer 2020 (S20) batch and raised $2 million in seed funding led by Costanoa Ventures, with participation from Y Combinator, The House Fund and SignalFire. The company was built to give data teams an open-source platform for collecting customer data and delivering it to their own warehouses.

The pace of feature releases has increased since the acquisition, with expanded production self-hosting, new enterprise controls and broader integration coverage giving customers more ways to operate reliable pipelines and partners more tools to serve their clients.

“We built Jitsu to give data teams control over their customer data and the freedom to run it on their own terms. Rohit and Priyank share that belief and bring hands-on experience building and operating software businesses. With Helium investing in engineering, support and integrations, we can deliver more for our customers and give partners a stronger platform to build on while preserving the open-source foundation that brought them to Jitsu.”

— Vladimir Klimontovich, Co-founder and CEO, Jitsu

The July release of Jitsu 2.14 gives self-hosted teams a Kubernetes operator, dedicated function servers and Kubernetes-native sync scheduling so they can scale workloads independently. Audit logs, expiring API tokens, maintenance mode and event reprocessing give customers more control over access and a clearer path to recovering failed deliveries.

New destinations include Resend, SendGrid, Statsig, DuckDB/MotherDuck and Xero, alongside expanded authentication options for Snowflake and Postgres. For agencies and technology partners, these integrations mean more client systems can connect through Jitsu with less custom development.

These releases build on Jitsu’s existing Management API and CLI and MCP server, which allow developers and AI agents to configure and debug pipelines.

“Our investment in Jitsu is focused on the work customers and partners do every day: keeping events flowing, connecting more tools and resolving problems quickly. The releases since the acquisition show that direction in practice. We will keep building on Jitsu’s open-source foundation so teams can grow with the product and choose how they run it.”

— Rohit Mittal, CEO, Helium Ventures

With the recent launch of reverse ETL, Jitsu now enables teams to send warehouse data back into their business tools. Jitsu also offers managed ClickHouse, giving teams a hosted analytics warehouse alongside their pipeline.

What Customers and Partners Can Expect

  • Continued choice and control — Jitsu remains MIT-licensed and free to self-host, with no usage limits. Existing Jitsu Cloud plans and pricing are unchanged, and customers do not need to take any action as a result of the acquisition.
  • Investment in day-to-day operations — Faster support and continued development will help customers resolve pipeline issues. New audit logs and event reprocessing give teams more visibility into changes and a way to recover failed deliveries.
  • More connections for partners — Broader integration coverage gives agencies and technology partners more ways to connect clients’ systems, reducing the need to build and maintain custom integrations.
  • Founder continuity — Vladimir Klimontovich, Jitsu’s co-founder and CEO, continues to advise the business.

Availability and Pricing

Jitsu is available as free, MIT-licensed software or through Jitsu Cloud. Cloud plans include 200,000 active events per month free, Business at $99 per month with 2 million active events included, and custom Enterprise plans. Additional active events on Business cost $40 per million. Visit jitsu.com/pricing for details or jitsu.com to get started.

About Jitsu

Jitsu participated in Y Combinator’s Summer 2020 (S20) batch and raised $2 million in seed funding led by Costanoa Ventures, with participation from Y Combinator, The House Fund and SignalFire. Founded in 2020, Jitsu is an open-source customer data platform for collecting and delivering event data to warehouses and downstream tools. Teams can self-host Jitsu or use Jitsu Cloud. Learn more at jitsu.com.

About Helium Ventures

Helium Ventures acquires and operates software businesses. Founded by Rohit Mittal and Priyank Singh, who previously co-founded Stilt, its portfolio includes InsurGrid, Maroo, That’s The One and Jitsu. Learn more at heliumventures.co.

Media Contact

Helium Ventures: [email protected]

SOURCE Helium Ventures

Senphonix Receives National Institutes of Health Grant to Advance SleeveSense, a Continuous, Long-Term Vitals Monitoring Platform

NIH SBIR funding from the National Heart, Lung, and Blood Institute advances the secure data platform behind a wearable designed to ease the burden of manual vital-signs checks and to support better-informed care whether in the hospital or at home.

MINNEAPOLIS, Oct. 13, 2026 — Senphonix, Inc., a medical technology startup developing SleeveSense™, a wearable designed to monitor patients’ vital signs continuously over days, weeks, or months at a time, today announced a Small Business Innovation Research (SBIR) Phase I award from the U.S. National Institutes of Health (NIH), through its National Heart, Lung, and Blood Institute (NHLBI). The award marks a major milestone for Senphonix: its second federal research grant in a matter of weeks, following a National Science Foundation (NSF) STTR Phase I award announced in September.

The NIH grant will fund testing of the platform’s software stack in a clinical environment, cloud and database scaling, and cybersecurity work toward SOC 2 Type II readiness. Taken together, it advances a platform built to address one of healthcare’s most persistent and costly problems: the manual, intermittent way patient vital signs are captured.

The two recent grants add to a fast-growing base of non-dilutive funding and partnership behind SleeveSense, spanning the NSF, the NIH, Microsoft, the Arizona Commerce Authority through the WearTech Applied Research Center, and the University of Arizona, reflecting growing momentum behind the problem it sets out to solve.

The need is significant and well documented. Nurses can spend up to and sometimes in excess of 20 percent of every shift taking and documenting vital signs manually, time drawn away from patient care. Because those readings are episodic, changes in a patient’s condition can go unseen between checks. After discharge, many patients are not monitored at all, creating a gap associated with costly, avoidable readmissions. Automated, always-on monitoring is intended to speak to each of these at once: reducing manual workload, supporting earlier awareness of a patient’s changing condition, and helping health systems pursue fewer readmissions and new remote-patient-monitoring revenue.

SleeveSense is a comfortable sleeve designed to be worn on the upper arm without interruption long-term, in and out of the hospital, and to deliver clinical-grade measurements, an accuracy target the company plans to validate in its upcoming clinical testing. It charges wirelessly, with no need to remove or handle the device. The commercial model is built to remove upfront financial risk for the hospital: Senphonix provides and manages all the infrastructure and only bills once a sleeve is assigned to a patient, so there is no capital outlay and nothing to pay for unused capacity.

“The barrier has never really been the sensor; it’s been building something hospitals can actually put to work and doing it with no upfront cost for them to try,” said Mike Haldane, Co-Founder and Co-CEO of Senphonix and principal investigator on the NIH award. “We designed SleeveSense to reduce manual workload and fit the way care teams already operate, with a light footprint and the clinical-grade accuracy we are validating in testing. NIH’s support helps us get the software clinically ready as we work toward bringing SleeveSense to market following FDA clearance.”

By design, the data is available to clinicians within the electronic health record, both during the hospital stay and after the patient goes home. Once discharged, patients can also view their own vitals through a simple mobile app that runs on its own with no action required. The work builds on the company’s NSF STTR Phase I award which funds development of the wearable’s wireless hardware and the software platform itself, so the two federal grants together move the device and its software from prototype toward clinical readiness.

Interest from the field is strong. In national studies sponsored by Senphonix, 98 percent of nurses (n=402) and 94 percent of healthcare CFOs (n=457) indicated they would support adopting SleeveSense within their organizations. Confidence level and margin of error for both studies were 95% and +/- 5% respectively.

“Two federal research awards in a matter of weeks, on top of private and state support, and clear demand from the nurses and CFOs who would use and buy it, tells us the market sees what we see,” said John Grant, PhD, Co-Founder and Co-CEO of Senphonix. “That combination of non-dilutive capital and real demand lets us move efficiently toward commercialization and the partnerships that will bring SleeveSense to health systems.”

Studies have shown that measurable changes in vital signs often precede serious adverse events, sometimes by hours. By monitoring without interruption in the hospital and at home, SleeveSense is designed to make those early changes easier to see and to give clinicians a fuller picture across the care continuum.

“For years, I watched companies try to make continuous wearable monitoring work in the real world, and every one of them ran into the same practical barriers that keep it out of hospitals,” said Mark Koppel, MD, a founding member of the Senphonix advisor team. “What convinced me about SleeveSense is that this team went after those friction points head-on, setting out to design around every one of them. That is what has been missing.”

Senphonix expects to begin a clinical study of SleeveSense in late 2026 or early 2027 and intends to pursue U.S. Food and Drug Administration (FDA) 510(k) clearance in early to mid-2027, following clinical testing. The NIH award follows the company’s implementation of its quality management system, establishment of manufacturing partnerships, and review of its clinical testing protocol with the FDA.

About Senphonix

Senphonix is a medical-technology company developing SleeveSense, a platform designed for continuous, comfortable, long-term vital-signs monitoring. It is being built to move with the patient across inpatient, outpatient, and at-home care, to fit hospital operations with a light footprint, and to be priced on a per-patient basis with the infrastructure managed by Senphonix. The company is a C-Corp based in Delaware, with offices in Arizona and Minnesota, and its core technology is exclusively licensed from the University of Arizona. Learn more at www.senphonix.com.

About the NIH SBIR Program

The Small Business Innovation Research (SBIR) program at the U.S. National Institutes of Health provides non-dilutive funding to U.S. small businesses to develop and commercialize innovative biomedical technologies that improve health and save lives.

Research reported in this press release is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number R43HL184398. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

SleeveSense is a device in development. It is not currently cleared or approved by the U.S. Food and Drug Administration and is not available for sale. Statements in this release regarding the device’s intended design, performance, and benefits describe development goals and have not been established. This release contains forward-looking statements about product development, regulatory plans, and future performance that involve risks and uncertainties; actual results may differ.

Market research was administered by MarketWise Advising, LLC, via national surveys conducted in 2025 and 2026 for Senphonix. Disclosure: Mike Haldane is both Founder/President of MarketWise Advising and Co-Founder/Co-CEO of Senphonix.

Media Contact

Michelle Gjerde, PR Specialist
Senphonix
[email protected] | 605-303-1934

Product photos are available upon request.

SOURCE Senphonix, Inc.

Lonergan Appoints Kirsten Settle and Michael Cunningham to Managing Partners

Deep tech executive search firm expands leadership after 25 years in business; publishes 2026 Lonergan Silicon Valley 150

BURLINGAME, Calif., Oct. 13, 2026 — Lonergan, the Silicon Valley premier executive search firm specializing in board, CEO and senior leadership for deep technology companies, today named Kirsten Settle and Michael Cunningham as Managing Partners.

The appointments cap a year of expansion. Since Mark Lonergan founded the firm in 2001, Lonergan Partners has helped build some of the global technology ecosystem’s most important public and private companies. About a quarter of its placements are CEOs in deep tech (semiconductors, AI infrastructure, networking, robotics and quantum computing), with the rest spanning boards and senior leadership. Now Settle and Cunningham, with nearly two decades and more than 250 senior searches between them, succeed Mark and lead Lonergan into its next era.

The firm opened an Austin office in 2024 as part of this mission and has launched a new website, logo, and brand identity with a new vector symbol evolving into a more architectural expression of leadership, ambition, and purposeful growth. Constructed from a series of intersecting planes, the mark reflects the moments where expertise, opportunity, and vision align. Individual elements come together to create something stronger, a visual metaphor for Lonergan’s role in helping organizations build leadership teams capable of shaping what comes next.

“Kirsten and Michael have been running our most consequential searches for years. This appointment formalizes what our clients already experience,” said Mark Lonergan, founder and chairman of Lonergan. “Our firm set out to build something more deliberate than bigger executive search companies: pairing the rigor, discipline, and resources of the world’s largest search organizations with personal accountability and precision, acting as a neighbor, not a distant advisor. Kirsten and Michael deliver this experience to clients every day.”

“Boards are hiring against a business leadership and technology roadmap that did not exist three years ago with the rise of new challenges around AI transformation, security and sustainability,” said Settle. “Michael and I are passionate about finding the right talent against these challenges. Our F18 proprietary process helps deepen engagement between Boards and CEO candidates ahead of a hire to ensure alignment and set the foundation for a smooth, successful transition. We believe this disciplined approach is what separates a good C-level hire from a lasting one.”

“Deep tech is no longer only a Silicon Valley story,” said Cunningham. “Our Austin office exists because the companies building chips and compute infrastructure are hiring across Texas, Arizona and throughout the US and Canada, and boards want an advisor who is present in those markets.”

SV 150

The firm also recently published the 2026 edition of the Lonergan Silicon Valley 150, its ranking of the region’s largest public technology companies, issued annually. This year’s edition reports record aggregate 2025 revenue of $2.3 trillion across the list and net income of $608 billion, up 41%. Combined market capitalization reached $20 trillion at the end of the first quarter of 2026, a 33.9% increase, and a record high of 42 Silicon Valley companies now sit in the S&P 500. Lonergan has worked with 51 LSV150-ranked companies since 2010. 

About Lonergan Partners

Lonergan Partners is a premier executive search advisor to the world’s leading technology companies, with deep roots in Silicon Valley and reach across North America. Founded in 2001, the firm specializes in board positions, CEO and C-level leadership in deep technology. Every engagement is led personally by a senior partner, from the first conversation to final placement. The firm publishes the Lonergan Silicon Valley 150, a ranking of the region’s largest public technology companies, and has authored Who Runs Silicon Valley since 2014. Lonergan Partners is headquartered in Burlingame, California, with an office in Austin, Texas. Learn more at lonerganpartners.com.

Media contact

Nicole Conley
Tanis Communications, Inc.
[email protected]

SOURCE Lonergan

MoonPay Names Anne Giviskos as Chief Financial Officer

Former Navan, NYSE and Euronext executive joins as MoonPay scales across financial markets

NEW YORK, Oct. 13, 2026 — MoonPay, the global financial technology company powering the movement of value across fiat and digital assets, today named Anne Giviskos as Chief Financial Officer. Anne most recently served as Interim CFO and Chief Accounting Officer at AI-powered business travel and expense platform Navan.

The appointment comes as MoonPay continues to build the operating system for value. In recent months, the company launched MoonPay Trade, giving applications and institutions access to more than 200 blockchains and protocols through a single API. It also acquired DFlow, a Solana trading infrastructure platform that has processed $45 billion in volume so far in 2026. DFlow transactions appear in more than 95% of Solana blocks daily, and MoonPay’s trading infrastructure now powers some of the largest crypto platforms, enabling Solana trades for Coinbase and cross-chain swaps in Ledger Wallet. The company also introduced PayBox, expanding its agentic finance offerings. In September, MoonPay entered into an agreement to acquire North Capital, expanding into onchain capital markets.

“Anne knows how to help ambitious companies navigate defining moments,” said Ivan Soto-Wright, founder and CEO of MoonPay. “She brings experience from public markets and fast-growing technology companies, along with the judgment and discipline to help MoonPay expand responsibly across payments, stablecoins and financial markets.”

With over two decades building and safeguarding the infrastructure of traditional markets, Anne brings deep expertise in scaling regulated financial businesses and integrating acquisitions. As CFO, Anne will lead the finance organization, set financial and capital strategy and build the infrastructure to support MoonPay’s next phase of growth.

Anne joins an expanding leadership team. MoonPay recently welcomed board members and advisors with experience spanning Wall Street, national security, Silicon Valley and digital assets.

“The way money moves is being rebuilt and MoonPay sits at the center of that shift, with the products, partners and global reach to lead it,” said Anne Giviskos. “I’m thrilled to join the team as MoonPay scales into the company this moment calls for.”

About MoonPay

MoonPay is a global financial technology company that provides infrastructure for moving value across traditional and digital financial systems. Founded in 2019, MoonPay serves more than 35 million customers in 180 countries and more than 1500 enterprise clients across crypto and fintech. Its products support payments, trading, commerce, stablecoin infrastructure and other services that connect conventional payment networks with blockchain-based financial rails. MoonPay maintains regulatory licenses and authorizations in multiple jurisdictions, including the United States and European Union. For more information, visit www.moonpay.com.

Media Contacts

MoonPay
[email protected]

SOURCE MoonPay

SAVORY CLOSES OVERSUBSCRIBED $200 MILLION FUND III — EYES AMERICA’S NEXT GREAT RESTAURANT BRANDS

With returning LPs and major financial institutions on board, the $201.5-million fund is already 35 percent deployed across four restaurant brands.

SALT LAKE CITY, Oct. 13, 2026 — Savory Fund, the private equity firm behind the breakout growth of restaurant category leaders Swig and Mo’ Bettahs, today announced the final close of Savory Fund III at $201.5 million, surpassing its $200 million target. The fund drew a mix of returning and new limited partners, including the country’s leading financial institutions, and has already deployed 35 percent of its capital.

“Raising a fund is a vote of confidence, and our investors voted loudly,” said Andrew K. Smith, co-founder and Managing Director of Savory Fund. “The majority of our third fund’s LPs invested with us in Fund I or II. They’ve been here as we’ve helped scale 13 restaurant brands across the country, from Detroit-style pizza to Nashville-style hot chicken to dirty soda, and I don’t take it for granted that they came back. Seeing major banks join them was a proud moment for us. It tells me people are starting to see restaurants the way we always have: these are real businesses that create jobs, anchor neighborhoods, and give people a place to gather. And when they’re run well, they are also strong, profitable investments. We’ve got four standout brands in Fund III already, and we’re just getting started.”

Fund III continues Savory’s strategy of partnering with profitable, emerging, founder-led restaurant concepts and pairing capital with a full operating platform led by CEO Clay Dover. The fund will ultimately include eight to nine portfolio companies across the quick-service, fast-casual, and casual dining segments.

Four investments are already in place:

South Block, a better-for-you acai and smoothie brand expanding beyond its home market in the Washington, D.C. area

Bonrue Bakery, a European-style patisserie with a devoted Utah following

Hawkers Asian Street Food, a Michelin Guide-recommended concept outperforming its category in AUVs and guest frequency

Zao Asian Grill, a fast-casual leader posting nearly 20% percent same-store sales growth

“Capital is the part of our business that’s easiest to explain, but it isn’t what sets Savory apart,” said Shauna K. Smith, co-founder and Managing Director of Savory Fund. “What our investors are really backing is the team behind the checks: operators who have opened restaurants, built playbooks, and know what it takes to scale without losing what made a brand special. Fund III gives us the runway to bring that expertise to more founders who are ready for their next chapter.”

Since its founding in 2018, Savory has grown to a portfolio of 13 restaurant brands spanning 400+ restaurants across 27 states. Its track record includes two of the most talked-about restaurant brands in the West. Under Savory’s partnership, Swig grew from 17 to 46 locations before Savory sold a majority stake to The Larry H. Miller Company in 2022. Mo’ Bettahs grew from six to 56 locations, more than nine times its original footprint, before Savory sold a majority stake to Blue Marlin Partners and Trive Capital in 2024. Savory remains a minority owner of both brands, and Andrew K. Smith continues to serve on both boards.

With four to five investments still ahead, Savory is actively evaluating new partnerships with founder-led brands ready to scale. To learn more, visit SavoryFund.com.

ABOUT SAVORY FUND

Savory is an innovative private equity firm that combines over $750M in assets under management with a growth playbook and expertise developed over 18 years of operating in the restaurant industry. Savory partners with high-potential, profitable, emerging restaurant brands to deliver financial capital, industry expertise, growth and revenue opportunities, profitability enhancements, and new location development. Founder involvement in the expansion of a brand is a central theme of the Savory approach. Savory is currently invested in the following brands: Swig, R&R BBQ, Pincho, Via 313 Pizzeria, Mo’ Bettahs, Saigon Hustle, Hash Kitchen, The Sicilian Butcher, Houston TX Hot Chicken, South Block, Bonrue Bakery, Hawkers Asian Street Food, and Zao Asian Grill. For more information, visit SavoryFund.com.

SOURCE Savory Fund

Runpod Surpasses $325 Million in ARR, Appoints Brian Erickson as Chief Financial Officer

AI Developer Cloud sees nearly 3x revenue growth since January as developer adoption and enterprise demand accelerate

SAN FRANCISCO, Oct. 13, 2026 — Runpod, the AI Developer Cloud, today announced that Brian Erickson has joined the company as Chief Financial Officer as Runpod surpasses $325 million in annual recurring revenue (ARR), up from $120 million in January 2026. Erickson brings more than 25 years of financial and operational leadership experience, including senior roles at DigitalOcean, Amazon and Microsoft, to support Runpod’s next phase of growth.

Runpod’s momentum is being driven by rapid developer adoption and growing enterprise demand for AI infrastructure. More than 1.2 million developers now build on Runpod, up from approximately 495,000 a year ago. September marked the platform’s biggest month on record, with more than 95,000 new signups.

Erickson joins Runpod from Suzy, an AI-powered consumer insights and market research platform, where he served as Chief Financial Officer. Previously, he was CFO of Transfix, a technology-enabled transportation marketplace, where he helped guide the company through a successful sale transaction. Earlier, Erickson held senior finance leadership roles at DigitalOcean, helping the cloud infrastructure provider scale profitably and navigate its initial public offering. He also held finance roles at Amazon and Microsoft, supporting the growth of their cloud computing businesses. Erickson holds a bachelor’s degree in business administration from the University of Notre Dame and an MBA from the University of Washington.

“Runpod has built something rare in cloud infrastructure: a platform that developers genuinely want to use, with enterprise adoption following naturally from that demand,” Erickson said. “Having spent much of my career helping cloud and technology companies scale, I see a tremendous opportunity to build on that foundation. I’m excited to help Runpod translate its developer momentum into a durable, category-defining business.”

More than one million developers at companies of all sizes trust Runpod for AI development: major global enterprises (Sony, Toyota, Intel), premier academic institutions (Columbia University, Cornell University, UCLA), and high-growth AI companies including Deep Cogito, Rendair, and Nodalview use Runpod to build and scale AI applications. Its platform supports the full AI development lifecycle, from training and fine-tuning to inference and deployment, without requiring developers to switch infrastructure as their needs evolve.

“We’ve grown nearly threefold this year because developers are building real businesses on Runpod, and those businesses are scaling fast,” said Zhen Lu, CEO and Co-founder of Runpod. “That creates enormous opportunity, but also demands a different level of financial and operational discipline. Brian has helped some of the world’s most successful cloud companies grow. He brings the experience to strengthen our financial and operational discipline as we scale.”

About Runpod

Runpod is the AI Developer Cloud. Purpose-built for AI workloads, Runpod provides the infrastructure AI developers need across the full lifecycle: experiment, train, fine-tune, deploy and scale. Over 1 million developers build on Runpod. From a solo developer’s first deployment to the largest AI teams running at scale, Runpod offers a fast, trusted path from AI experiment to production. Learn more at runpod.io.

SOURCE Runpod